ALRN — Aileron Therapeutics Balance Sheet
0.000.00%
- $50.26m
- $73.35m
Annual balance sheet for Aileron Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 18.3 | 13.8 | 45.9 | 21.2 | 17.3 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 19.6 | 16.3 | 48.2 | 21.9 | 18.3 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 6.36 | 0.015 | 0.28 | 0.11 | 0.019 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 26.5 | 16.3 | 48.5 | 22 | 106 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Current Liabilities | 5.84 | 3.96 | 4.51 | 3.38 | 4.38 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 10.4 | 4.18 | 4.58 | 3.38 | 7.71 |
Redeemable Preferred Stock | |||||
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 16 | 12.2 | 43.9 | 18.6 | 98.3 |
Total Liabilities & Shareholders' Equity | 26.5 | 16.3 | 48.5 | 22 | 106 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |